Risk of End-Stage Kidney Disease and Topiramate Use.

ABSTRACT:

Introduction

Topiramate is widely used for migraine prevention but has pleiotropic effects on renal sodium reabsorption and inflammation. Whether these effects could be associated with lower risk of end-stage kidney disease (ESKD) and cardiovascular outcomes is unknown.

Methods

Among 1,745,580 patients with a diagnosis of migraine, the risk of ESKD, cardiovascular outcomes, and death was assessed after propensity matching in patients treated with topiramate versus untreated patients.

Results

Overall, 317,936 patients treated with topiramate were properly matched with 317,936 controls by age (43 years old), sex (women: 86%), clinical and biological parameters, comorbid conditions, and baseline medications. After a median follow-up of 3.5 years, patients receiving topir

SUBMITTER: Halimi JM 

PROVIDER: S-EPMC12347801 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature